Outcome of Press Release/Media Release Under Regulation 30 of SEBI ( Listing Obligation and Disclosure Requirements) Regulation, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.4 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Asarfi Hospital reported a strong Q3 FY26 (quarter ended December 31, 2025) with standalone revenue rising 40% year-on-year to ₹46.06 crore (₹32.89 crore in Q3 FY25). Profit after tax more than doubled, up 102% YoY to ₹5.48 crore, with EPS at ₹2.79 versus ₹1.38. EBITDA grew 45% YoY to ₹10.12 crore (margin at 22%) and EBIT rose 81% YoY to ₹6.76 crore, driven by higher patient volumes, improved ARPOB, and a better case mix. For the nine-month period, standalone revenue grew 46% to ₹126.57 crore and PAT rose 81% to ₹12.98 crore. Operational metrics were strong, with IPD revenue up 42% YoY and OPD revenue up 37% YoY, led by Cardiology, Neurosciences, Head & Neck, and Haemato-Oncology. The consolidated results were largely in line with standalone figures.
This is a positive performance update showing strong top-line growth, expanding margins, and improved profitability, which should be viewed favorably by shareholders. The company has not raised any concerns about sustainability or flagged any adverse auditor remarks, suggesting operational momentum is intact.